clinical trial · NCT04185415
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
UCB Biopharma SRL·phase1·completed·n = 25
Progressive Supranuclear PalsybepranemabPlacebo
brief summary
The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).
started
Dec 3, 2019
primary completion
Nov 17, 2021
completion
Nov 17, 2021
last updated
Dec 1, 2023
official title
A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol